Results 171 to 180 of about 19,808 (220)

[^99mTc]Tc-antigranulocyte scintigraphy for prediction of bone marrow reserve prior to radioligand therapy in patients with metastatic castration resistant prostate cancer. [PDF]

Eur J Nucl Med Mol Imaging
Kunte SC, Delker A, Holzgreve A, Zacherl MJ, Scheifele M, Casuscelli J, Gildehaus FJ, Unterrainer M, Ilhan H, Werner RA, Unterrainer LM.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy

Clinical Nuclear Medicine, 2022
Abstract 177Lu-PSMA-617 radioligand therapy (RLT) has evolved as a suitable alternative to existing therapeutic options in patients with metastatic castration-resistant prostate cancer. With the emergence of α-emitters such as 225Ac, the efficacy of PSMA-RLT has further improved. Xerostomia and myelosuppression are
Swayamjeet, Satapathy, Amit, Sharma, Ashwani, Sood, Pooja, Maheshwari, Harinder Jit Singh, Gill   +4 more
openaire   +2 more sources

New Horizons in Radioligand Therapy

Clinical Nuclear Medicine, 2023
Abstract An 85-year-old man with advanced metastatic castration-resistant prostate cancer and progression after 8 cycles of 177Lu–prostate-specific membrane antigen (PSMA)–617 radioligand therapy (RLT) received 1 cycle of 161Tb-PSMA RLT. This one administration of 6.5 GBq 161Tb-PSMA-617 resulted in impressive partial remission with a PSA ...
Florian, Rosar, Stephan, Maus, Andrea, Schaefer-Schuler, Caroline, Burgard, Fadi, Khreish, Samer, Ezziddin   +5 more
openaire   +2 more sources

Long-Term Nephrotoxicity of¹⁷⁷Lu-PSMA Radioligand Therapy

Journal of Nuclear Medicine, 2023
β-emitting 177Lu targeting prostate-specific membrane antigen (PSMA) is an approved treatment option for metastatic castration-resistant prostate cancer. Data on its long-term nephrotoxicity are sparse. This study aimed to retrospectively evaluate post-177Lu-PSMA estimated glomerular filtration rate (eGFR) dynamics for at least 12 mo in a cohort of ...
Steinhelfer, Lisa, Lunger, Lukas, Cala, Lisena, Pfob, Christian H., Lapa, Constantin, Hartrampf, Philipp E., Buck, Andreas K., Schäfer, Hannah, Schmaderer, Christoph, Tauber, Robert, Brosch-Lenz, Julia, Haller, Bernhard, Meissner, Valentin H., Knorr, Karina, Weber, Wolfgang A., Eiber, Matthias   +15 more
openaire   +3 more sources

Covalent targeted radioligands potentiate radionuclide therapy

Nature
Targeted radionuclide therapy, in which radiopharmaceuticals deliver potent radionuclides to tumours for localized irradiation, has addressed unmet clinical needs and improved outcomes for patients with cancer1-4. A therapeutic radiopharmaceutical must achieve both sustainable tumour targeting and fast clearance from healthy tissue, which remains a ...
Xi-Yang Cui, Zhu Li, Ziren Kong, Yu Liu, Hao Meng, Zihao Wen, Changlun Wang, Junyi Chen, Mengxin Xu, Yiyan Li, Jingyue Gao, Wenjia Zhu, Zhixin Hao, Li Huo, Shaoyan Liu, Zhi Yang, Zhibo Liu   +16 more
openaire   +2 more sources

Tumor Lysis Syndrome Following PSMA Radioligand Therapy

Clinical Nuclear Medicine
Abstract Tumor lysis syndrome (TLS) is a rare complication following treatment in prostate cancer patients. We present a 65-year-old man with history of castration-resistant prostate cancer who developed TLS following 2 sessions of 177Lu-PSMA therapy. The patient presented with bulky axillary and mediastinal lymphadenopathies, an unusual site
Pegah Sahafi, Michael Saeed, Mohammad Hadi Samadi, Kamran Aryana, Emran Askari   +4 more
openaire   +2 more sources

Prostate-specific membrane antigen radioligand therapy of prostate cancer

The Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2019
Defining an optimal therapeutic approach in metastatic castration-resistance prostate cancer (mCRPC) patients in advanced stages is still challenging in routine clinical practice. Prostate-specific membrane antigen (PSMA) targeted radionuclide therapy with β- or α-emitters such as 177-Lutethium (177Lu) or 225-Actinium (225A) has been a main focus at ...
Mohsen, Beheshti, Alexander, Heinzel, Dirk, von Mallek, Christian, Filss, Felix M, Mottaghy   +4 more
openaire   +2 more sources

Radioligand Therapy in Prostate Cancer Using PSMA Ligands

2020
Patients with metastatic castration-resistant prostate cancer (mCRPC) have limited therapeutic options. Following a theranostics strategy, targeting the prostate-specific membrane antigen (PSMA) by diagnostic and therapeutic radioisotopes is an evolving field in the management of mCRPC.
Robert Seifert, Kambiz Rahbar
openaire   +1 more source

Pentixather: paving the way for radioligand therapy in oncohematology

Expert Review of Anticancer Therapy
not ...
Bauckneht M, Filippi L
openaire   +3 more sources